We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

100 hedge funds and large institutions have $579M invested in Aclaris Therapeutics in 2016 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 40 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

717% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 6

471% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 7

300% more funds holding in top 10

Funds holding in top 10: 2 → 8 (+6)

84% more ownership

Funds ownership: 0% → 84% (+84%)

72% more funds holding

Funds holding: 58 → 100 (+42)

46% more capital invested

Capital invested by funds: $396M → $579M (+$183M)

Holders
100
Holders Change
+42
Holders Change %
+72.41%
% of All Funds
2.5%
Holding in Top 10
8
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+300%
% of All Funds
0.2%
New
49
Increased
40
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$21.2M
2
PC
PointState Capital
New York
+$18.3M
3
Invesco
Invesco
Georgia
+$15.9M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11.5M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$11.4M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$55.9M
2
RCM
RA Capital Management
Massachusetts
-$39.6M
3
VC
Vivo Capital
California
-$23.1M
4
Fidelity International
Fidelity International
Bermuda
-$4.85M
5
GTC
Ghost Tree Capital
New York
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$4.63M +$983K +38,570 +29%
CCI
27
Columbus Circle Investors
$4.33M +$4.07M +159,678 New
FCMI
28
Foresite Capital Management III
California
$4.23M +$3.97M +155,767 New
Northern Trust
29
Northern Trust
Illinois
$4.12M +$1.09M +42,583 +39%
EI
30
EAM Investors
California
$3.76M +$2.72M +106,649 +334%
SCM
31
Sio Capital Management
New York
$3.76M +$3.53M +138,441 New
SC
32
Samlyn Capital
New York
$3.69M +$3.47M +136,000 New
GPCM
33
Granite Point Capital Management
Massachusetts
$3.56M +$2.42M +95,000 +264%
MIM
34
Monashee Investment Management
Massachusetts
$3.44M +$3.23M +126,700 New
GTC
35
Ghost Tree Capital
New York
$3.26M -$1.4M -55,000 -31%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$3.12M +$1.73M +68,044 +146%
Deutsche Bank
37
Deutsche Bank
Germany
$2.99M +$1.5M +58,688 +114%
Geode Capital Management
38
Geode Capital Management
Massachusetts
$2.82M +$1.35M +52,765 +103%
Alyeska Investment Group
39
Alyeska Investment Group
Illinois
$2.66M +$2.5M +97,854 New
RG
40
Redmile Group
California
$2.56M +$2.4M +94,200 New
EU
41
Emory University
Georgia
$2.46M +$2.31M +90,704 New
NIP
42
Nicholas Investment Partners
California
$1.86M +$555K +21,767 +47%
HighTower Advisors
43
HighTower Advisors
Illinois
$1.69M +$265K +10,402 +20%
Morgan Stanley
44
Morgan Stanley
New York
$1.59M +$813K +31,869 +118%
Victory Capital Management
45
Victory Capital Management
Texas
$1.52M +$1.43M +56,160 New
Russell Investments Group
46
Russell Investments Group
United Kingdom
$1.41M +$1.33M +52,124 New
IHM
47
Iguana Healthcare Management
New York
$1.36M +$1.27M +50,000 New
Ameriprise
48
Ameriprise
Minnesota
$1.31M +$1.23M +48,146 New
EEG
49
E.E. Geduld
$1.22M +$575K +22,561 +100%
JGC
50
J. Goldman & Co
New York
$1.15M +$1.08M +42,173 New
1
2
3 4 5

ACRS Hedge Fund Activity: Q4 2016 in Review

100 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2016, worth a combined $579M — up 46% from $396M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new ACRS positions and 6 closed out — a net gain of 43 holders — while 40 added to existing stakes and 7 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $21.2M. The largest seller was Fidelity Investments, cutting an estimated $55.9M.

  • 100 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2016, up from 58 in Q3 2016.
  • Funds reported $579M of Aclaris Therapeutics stock for Q4 2016, up 46% quarter-over-quarter.
  • 49 funds opened new Aclaris Therapeutics positions in Q4 2016 and 6 closed out, a net change of +43 holders.
  • The largest Aclaris Therapeutics buyer in Q4 2016 was Perceptive Advisors, an estimated $21.2M added.
  • The largest Aclaris Therapeutics seller in Q4 2016 was Fidelity Investments, an estimated $55.9M sold.

Based on aggregated 13F filings for Q4 2016.